Month: September 2022

A GIGANTIC STUDY OF DISEASE GENES AND HUMAN MIGRATION. This impressive study is an example of adaptation and acquisition of not so good genetic traits. Data mining this is likely to yield valuable clues to disease genes. http://lnkd.in/J5JXRB View in LinkedIn

DR. ANDREU MAS-COLELL, CATALAN'S MINISTER OF ECONOMY, weighs in about the Spain-Catalan economic disparity issue at the heart of the Independence movement in Catalunya. Even other autonomous regions of Spain have cut fairer deals with Madrid. http://www.catalannewsagency.com/news/politics/catalonia-contributed-85-its-gdp-infrastructures-and-services-rest-spain-2010 View in LinkedIn

CATALUNYA AND SPAIN DIFFER OVER NEW RAIL ROUTE, that would be key to Catalan commerce, and in the contentious climate of the independence movement, the Madrid position appears to have ossified irrationally. http://lnkd.in/d9KQBs View in LinkedIn

BRUCE BOOTH OF ATLAS VENTURES deftly summarizes three of the hottest IPOs in years, concluding that, for now at least, the ROI has been disappointing, and that to achieve higher returns closer to 3x, valuations at exit need to move higher. This is true if the investor exits close to the IPO mark, rather than wait for the market to increase the value per share following good news in the clinic. Regardless, these are overall positive steps in a market where liquidity is returning at long last. http://lnkd.in/ypRrDq View in LinkedIn

OPENING IPO MARKETS FOR LIFE SCIENCE COMPANIES loosen the severe capital liquidity drought of the past five years. This promising development may lead to VCs again swinging back to favor the sector after an equally long disaffection. http://lnkd.in/Dund3M View in LinkedIn

THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE again shows bold initiative to attract the top names to create a critical mass. This will become doubly significant as Japan's strategic initiative to prioritize pluripotent stem cell therapies kicks into action, and gives this traditionally underfunded and undervalued sector the horsepower that it needs. It will become the third leg of medicine's stool -- drugs, biologicals and now stem cells. http://lnkd.in/BDqXNE View in LinkedIn

INCREASED R&D SPENDING BY TOP TEN BIOTECH COMPANIES, may be good news, provided the lesson from Big Pharma is remembered. Big Research can result in big disappointments. Skunk works and SMEs have consistently punched above their weight in performance and been less prone to the Not Invented Here (NIH) syndrome that haunts large research undertakings. Undoubtedly subject matter for future B-School case studies, this is a clear trend. http://lnkd.in/jU3bAR View in LinkedIn

BIG PHARMA'S SPENDING REFLECTS ITS TRUE MUSCLE, namely marketing and sales. These big organizations are powerful sales machines and cannot be rivaled by small companies, particularly in big physician access. In the case of specialty doc access, however, smaller specialty Pharma companies perform well, and in the case of generics, only very small sales forces are needed. http://lnkd.in/8CmrBM View in LinkedIn

PRESS RELEASES IN ENGLISH are critical to gain visibility in the Biopharma community both on your website and through newswire services. However, as the world shrinks and more countries have significant Biopharma research companies, it is increasingly important to include press releases through Asian outlets in appropriate languages. This is an important step in slowly developing a credible world presence in the internet. Too many European technology companies fail to do either. http://lnkd.in/7PSK42 View in LinkedIn

BIO-BILLIONAIRES FUND COLLABORATIVE TRANSLATIONAL RESEARCH FACILITY IN GENEVA. This is one more investment in the future of Biopharma which is made by seasoned veterans, who are clearly optimistic about the industry's future. The clustering of expertise and international connections is invaluable for SME Biopharma companies. http://lnkd.in/BT5E97? View in LinkedIn